IMPROvE-CED Trial: Intracoronary Autologous CD34+ Cell Therapy for Treatment of Coronary Endothelial Dysfunction in Patients With Angina and Non-Obstructive Coronary Arteries

Conclusion: A single IC autologous CD34+ cell infusion was safe and may potentially be an effective disease-modifying therapy for microvascular CED in humans. Clinical Trial Registration: NCT03471611.PMID:34923853 | DOI:10.1161/CIRCRESAHA.121.319644

Source: Circulation Research - December 20, 2021 Category: Cardiology Authors: Michel T Corban Takumi Toya Diana P Albers Faten Sebaali Bradley Lewis John P Pearce Bois Rajiv Gulati Abhiram Prasad Patricia J Best Malcolm Bell Charanjit Rihal Megha Prasad Ali Ahmad Lilach O Lerman Mary L Solseth Jeffrey L Winters Allan B Dietz Amir L Source Type: research